NEW YORK, June 9, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:TuHURA Biosciences, Inc. (NASDAQ: HURA)'s merger with Kineta, Inc. If you are a TuHURA shareholder, click here to learn more about your legal rights and options.Vigil Neuroscience, Inc. (NASDAQ: VIGL)'s sale to Sanofi. Under the terms of the proposed transaction, V ...

Vigil Neuroscience, Inc. (VIGL) closed the last trading session at $7.88, gaining 225.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10 indicates a 26.9% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $5.29. While the lowest estimate of $8 indicates a 1.5% increase from the current price level, the most optimistic analy ...

PHILADELPHIA, June 4, 2025 /PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Vigil Neuroscience, Inc. ("Vigil") (NASDAQ: VIGL) shareholders. Click here for additional information about your legal rights and options: https://kaskelalaw.com/case/vigil- neuroscience/ On May 21, 2025, Vigil announced that it had agreed to be acquired by Sanofi at an upfront price of $8.00 per share in cash plus a non-transferable continge ...

WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). Iluzanebart demonstrated a favorable ...

Group 1 - Vigil Neuroscience, Inc. (VIGL) has recently experienced a "golden cross" event, indicating a potential bullish breakout from a technical perspective [1][2] - A golden cross occurs when a stock's short-term moving average, typically the 50-day, crosses above its long-term moving average, such as the 200-day, suggesting stronger breakouts [2] - VIGL has rallied 186.9% over the past four weeks, and it currently holds a 2 (Buy) rating on the Zacks Rank, indicating a strong potential for further gains [4] Group 2 - The bullish outlook for VIGL is supported by a positive earnings forecast, with five upward revisions in earnings estimates over the past 60 days and no downward revisions [4][6] - The combination of the positive technical indicators and the favorable earnings outlook suggests that investors should monitor VIGL for potential gains in the near future [6]

Group 1 - Class Action Attorney Juan Monteverde's firm, Monteverde & Associates PC, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1] - Vigil Neuroscience, Inc. (NASDAQ: VIGL) is under investigation regarding its proposed merger with Sanofi, which includes an upfront payment of $8.00 per share in cash [1] - The total equity value of the transaction, including a potential contingent value right (CVR) payment of $2.00 per share, is approximately $600 million on a fully diluted basis [1]

Shares of Vigil Neuroscience, Inc. (VIGL) have gained 340.2% over the past four weeks to close the last trading session at $7.88, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.71 indicates a potential upside of 86.7%.The mean estimate comprises seven short-term price targets with a standard deviation of $4.75. While the lowest estimate of $8 indicates a 1.5% increase from ...

Core Viewpoint - Sanofi has entered into a definitive merger agreement to acquire Vigil Neuroscience for an upfront payment of $8.00 per share, with potential additional payments based on the commercial success of VG-3927, valuing the total equity of the transaction at approximately $600 million on a fully diluted basis [1][5][6]. Company Overview - Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring the function of microglia, the immune cells of the brain [11]. - The company is developing VG-3927, a small molecule TREM2 agonist aimed at treating Alzheimer's disease, and has a pipeline that includes therapies for both rare and common neurodegenerative diseases [11]. Transaction Details - The merger agreement stipulates that Vigil's shareholders will receive $8.00 per share in cash at closing, plus a contingent value right (CVR) that could yield an additional $2.00 per share upon the first commercial sale of VG-3927 [1][5][6]. - The acquisition is expected to close in the third quarter of 2025, subject to customary conditions including shareholder approval and regulatory clearances [8]. Strategic Rationale - Sanofi's acquisition of Vigil aligns with its strategic focus on neurology and the development of innovative therapies for critical unmet needs in neurodegenerative diseases [4]. - The TREM2 target is seen as a promising area for addressing immune dysregulation and neurodegeneration, particularly in Alzheimer's patients who currently have limited treatment options [4][2]. Development Potential - The acquisition is anticipated to strengthen the development path for VG-3927, which is positioned as a Phase 2-ready clinical candidate for Alzheimer's disease [5][6]. - Activating TREM2 is expected to enhance the neuroprotective function of microglia, potentially preventing neural degeneration associated with adult-onset neurodegenerative diseases [2][3].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-41200 VIGIL NEUROSCIENCE, INC. (Exact name of Registrant as specified in its Charter) De ...

Exhibit 99.1 Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates – On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – - Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May. 7, 2025 — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neur ...